TREDEGAR CORP
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
TG$5.90+9.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders' Equity
| Common Stock · RetainedEarnings · Trust for Savings Restoration Plan · Accumulated Other Comprehensive Income (Loss) · Total Shareholders’ Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands, except share and per-share data) · Shares · Amount | ||||||||
| Balance at January 1, 2023 | 34,000,642 | $58,824 | $292,721 | $(2,188) | $(147,595) | $201,762 | ||
| Net income (loss) | — | — | (105,905) | — | — | (105,905) | ||
| Foreign currency translation adjustment | — | — | — | — | 3,042 | 3,042 | ||
| Derivative financial instruments adjustment | — | — | — | — | 3,281 | 3,281 | ||
| Net gains or (losses) and prior service costs | — | — | — | — | 1,513 | 1,513 | ||
| Amortization of prior service costs and net gains or losses | — | — | — | — | 7,065 | 7,065 | ||
| Recognition in earnings of net actuarial loss for pension settlement | — | — | — | — | 50,997 | 50,997 | ||
| Cash dividends declared ($0.26 per share) | — | — | (8,884) | — | — | (8,884) | ||
| Stock-based compensation expense | 407,996 | 3,036 | — | — | — | 3,036 | ||
| Repurchase of employee common stock for tax withholdings | — | (254) | — | — | — | (254) | ||
| Tredegar common stock purchased by trust for savings restoration plan | — | — | 45 | (45) | — | — | ||
| Balance at December 31, 2023 | 34,408,638 | 61,606 | 177,977 | (2,233) | (81,697) | 155,653 | ||
| Net income (loss) | — | — | (64,565) | — | — | (64,565) | ||
| Foreign currency translation adjustment | — | — | — | — | (295) | (295) | ||
| Foreign currency translation loss realized on the sale of Terphane | — | — | — | — | 88,437 | 88,437 | ||
| Derivative financial instruments adjustment | — | — | — | — | 755 | 755 | ||
| Derivative financial instruments loss realized on the sale of Terphane | (1,288) | (1,288) | ||||||
| Net gains or (losses) and prior service costs | — | — | — | — | 397 | 397 | ||
| Amortization of prior service costs and net gains or losses | — | — | — | — | (110) | (110) | ||
| Stock-based compensation expense | 252,634 | 2,211 | — | — | — | 2,211 | ||
| Repurchase of employee common stock for tax withholdings | — | (227) | — | — | — | (227) | ||
| Balance at December 31, 2024 | 34,661,272 | 63,590 | 113,412 | (2,233) | 6,199 | 180,968 | ||
| Net income (loss) | — | — | 33,476 | — | — | 33,476 | ||
| Foreign currency translation adjustment | — | — | — | — | 461 | 461 | ||
| Derivative financial instruments adjustment | — | — | — | — | 803 | 803 | ||
| Net gains or (losses) and prior service costs | — | — | — | — | (48) | (48) | ||
| Amortization of prior service costs and net gains or losses | — | — | — | — | (199) | (199) | ||
| Recognition in earnings of net actuarial gain for other postretirement benefit termination | — | — | — | — | (794) | (794) | ||
| Stock-based compensation expense | 76,262 | 2,476 | — | — | — | 2,476 | ||
| Repurchase of employee common stock for tax withholdings | — | (589) | — | — | — | (589) | ||
| Balance at December 31, 2025 | 34,737,534 | $65,477 | $146,888 | $(2,233) | $6,422 | $216,554 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.